Taiwan Stock Exchange · Healthcare
Sinphar Pharmaceutical stock from India: price, numbers and tax
Sinphar Pharmaceutical (1734) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Sinphar Pharmaceutical at a glance
- Price
- NT$32.10-NT$0.00 (0.00%)
- Market cap
- NT$6.47B
- Day range
- NT$31.80 – NT$32.10
- P/E
- 17.26
- Dividend yield
- 2.94%
- Volume
- 156.46K
- 1 month
- +4.90%
- 6 months
- +14.52%
- YTD
- +18.28%
- 1 year
- +17.28%
- 5 years
- +2.52%
Sinphar Pharmaceutical statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$3.4B | NT$3.2B | NT$3.0B | NT$2.9B | NT$2.4B |
| Gross profit | NT$1.5B | NT$1.2B | NT$1.1B | NT$1.1B | NT$888.7M |
| Operating income | NT$416.9M | NT$294.0M | NT$286.1M | NT$197.8M | −NT$180.2M |
| Net income | NT$365.8M | NT$304.7M | NT$375.2M | NT$224.6M | −NT$38.1M |
| Earnings per share | NT$1.92 | NT$1.68 | NT$2.07 | NT$1.24 | −NT$0.21 |
| EBITDA | NT$689.7M | NT$601.2M | NT$582.9M | NT$539.6M | NT$109.6M |
| Total assets | NT$6.2B | NT$6.3B | NT$6.3B | NT$6.2B | NT$6.2B |
| Total debt | NT$1.5B | NT$1.9B | NT$1.9B | NT$1.9B | NT$2.1B |
| Cash and short-term investments | NT$994.6M | NT$1.2B | NT$1.1B | NT$1.2B | NT$1.2B |
| Shareholders' equity | NT$3.4B | NT$3.3B | NT$3.1B | NT$2.9B | NT$2.7B |
| Operating cash flow | NT$584.7M | NT$593.5M | NT$296.4M | NT$425.3M | NT$135.5M |
| Free cash flow | NT$383.7M | NT$336.8M | −NT$4.6M | NT$271.9M | −NT$25.9M |
| Capital expenditure | −NT$200.9M | −NT$256.7M | −NT$300.9M | −NT$153.4M | −NT$161.4M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Locus Cell | 6891.TWO | $42.45 | $8.51B |
| Savior Lifetec | 4167.TWO | $19.60 | $6.50B |
| TaiGen Biopharmaceuticals | 4157.TWO | $8.73 | $6.21B |
| Hi-Clearance | 1788.TWO | $127.50 | $5.68B |
| OBI Pharma | 4174.TWO | $43.10 | $5.67B |
| Pacific Hospital Supply | 4126.TWO | $78.00 | $5.66B |
| Mycenax Biotech | 4726.TWO | $23.40 | $4.84B |
| Panion & Bf Biotech | 1760.TW | NT$54.60 | NT$4.68B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Sinphar Pharmaceutical from India
What Sinphar Pharmaceutical does
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. Sinphar Pharmaceutical operates in the Medical - Pharmaceuticals industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Sinphar Pharmaceutical shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.